Help
RSS
API
Feed
Maltego
Contact
Domain > www.lonsurfhcp.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2020-09-13
13.225.31.49
(
ClassC
)
2024-08-11
99.84.66.73
(
ClassC
)
2025-04-08
99.84.66.118
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: CloudFrontDate: Sun, 11 Aug 2024 20:11:20 GMTContent-Type: text/htmlContent-Length: 167Connection: keep-aliveLocation: https://www.lonsurfhcp.com/X-Cache: Redirec html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>CloudFront/center>/body>/html>
Port 443
HTTP/1.1 200 OKContent-Type: text/html; charsetutf-8Content-Length: 57254Connection: keep-aliveCache-Control: privateCache-Control: no-cacheset-cookieDate: Sun, 11 Aug 2024 20:11:21 GMTSet-Cookie: sho !DOCTYPE html>!--if lt IE 9>html langen classie8>!endif-->!--if (gt IE 9)|!(IE)>!-->html langen>!--!endif-->head> meta charsetutf-8 /> meta nameviewport contentwidthdevice-width, initial-scale1.0> title>LONSURF® (trifluridine and tipiracil) tablets | Approved for use in Combination with bevacizumab as a 3L Treatment for Metastatic Colorectal Cancer/title> meta namedescription contentLONSURF is approved for use in combination with bevacizumab for 3L metastatic colorectal cancer as seen in the SUNLIGHT trial. LONSURF is also indicated as a single agent for patients with previously treated metastatic colorectal and gastric or GEJ cancer. Please see Important Safety Information and full Prescribing Information.> link relicon typeimage/jpg href/Content/img/favicon.ico /> link relcanonical hrefhttps://www.lonsurfhcp.com> meta propertyog:title contentLONSURF® (trifluridine and tipiracil) tablets for HCPs | Approved for Use in Combination with bevacizumab /> meta propertyog:description contentFind out more about LONSURF + bevacizumab including Prescribing Information and Important Safety Information. /> meta propertyog:site_name content /> meta propertyog:image contenthttps://www.lonsurfhcp.com/Content/img/lonsurf-logo.png /> meta propertyog:image:alt contentLONSURF® (trifluridine and tipiracil) tablets logo /> meta propertyog:url contenthttps://www.lonsurfhcp.com /> script typeapplication/ld+json> { @context: https://schema.org, @type: VideoObject, publisher: { @type: Organization, name: The New England Journal of Medicine } , author: { @type: Organization, name: The New England Journal of Medicine } , name: The New England Journal of Medicine: Combination Therapy for Progressive Colorectal Cancerr, description: This video summarizes the SUNLIGHT trials research and findings for LONSURF® + Bevacizumab, a third line combination therapy for the treatment of metastatic colorectal cancer, thum
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]